bluebird bio Inc <BLUE.O>: A loss of $1.12 per share anticipated for third quarter

November 01, 2022 11:38 AM PDT | By Reuters
Follow us on Google News:

1 November 2022 06:37 p.m. All figures in US dollars. bluebird bio Inc is expected to show an increase in its third quarter earnings to $-1.12​ per share according to the mean Refinitiv estimate from ten analysts. Wall Street expects results to range from a loss of $-1.30 to ​a loss of -88 cents per share. RECOMMENDATIONS * The consensus recommendation for the company is "Hold". This includes one "Buy", eight "Hold", * The average consensus recommendation for the biotechnology & medical research peer group is also "Hold". FORECAST CHANGES * Eleven analysts are currently providing Refinitiv with estimates. * In the last week there have been no earnings estimate revisions by analysts covering the company. There were no changes to the number of estimates. * In the last four weeks the earnings per share estimate has risen by 0.18 percent from $-1.11. Estimates ranged from a high of -88 cents to a low of $-1.28. There has been no changes to the number of estimates. * The StarMine predicted earnings surprise is too low to be considered statistically significant. Predicted revenue surprise is too low to be significant. * The average price target from the eleven analysts providing estimates is $7.56. YEAR OVER YEAR * The company is expected to report a fall in revenue to $1 million from $22.68 million in the same quarter last year. * The current quarter consensus estimate of $-1.12 per share implies a gain of 64.65 percent from the same quarter last year when the company reported $-3.16 per share. * Previous quarterly performance (using preferred earnings measure) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET, MISSED Jun. 30 2022 -1.24 -1.27 Missed Mar. 31 2022 -1.39 -1.66 Missed Dec. 31 2021 -1.88 -2.14 Missed Sep. 30 2021 -2.59 -3.16 Missed This summary was machine generated from Refinitiv data November 1 at 06:37 p.m..


The above content is directly sourced from Reuters under a contractual arrangement. The content is being provided as a convenience and for informational purposes only; and does not constitute an endorsement or approval by Kalkine Media of any of the products, services, or opinions of the organization or individual. The user is apprised that Kalkine Media bears no responsibility for the accuracy, legality, or content of Reuters, any external sites, or for that of subsequent links. The user is requested to contact Reuters directly for answers to questions regarding the content. Please note that Kalkine Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

Top Listed Companies